Loratadine
- Generic Name
- Loratadine
- Brand Names
- Alavert, Alavert D, Allerclear, Claritin, Claritin-D, Diphen, Loradamed, Wal-itin, Wal-itin D
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23ClN2O2
- CAS Number
- 79794-75-5
- Unique Ingredient Identifier
- 7AJO3BO7QN
- Background
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
- Indication
Loratadine is a 2nd generation antihistamine and is used to manage symptoms of allergic rhinitis, wheal formation, urticaria, and other allergic dermatologic conditions.
- Associated Conditions
- Allergic Dermatologic Disorders, Allergic Reaction, Allergic Rhinitis (AR), Allergy to Tree Pollen, Chronic Urticaria, Common Cold, Epiphora, Eye pruritus, Fever, Nasal Congestion, Nasal Itching, Pain, Perennial Allergic Rhinitis (PAR), Pruritus, Rhinitis Perennial, Rhinorrhoea, Seasonal Allergic Rhinitis, Sneezing, Sensation of burning in the eyes, Watery itchy eyes
- Associated Therapies
- -
Observation of Use of Claritin (Loratadine) Tablet, RediTabs, and Dry Syrup in Children (Study P05834)(COMPLETED)
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-09-30
- Last Posted Date
- 2015-02-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1003
- Registration Number
- NCT00762983
Post Approval Pharmacokinetic Study of Loratadine in Japanese Pediatric and Adult Patients (Study P05539)
- First Posted Date
- 2008-08-08
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 261
- Registration Number
- NCT00730912
Efficacy and Safety of Omalizumab in Adults (18-70 Years) With Moderate to Severe Chronic Urticaria
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-06-04
- Last Posted Date
- 2011-10-21
- Lead Sponsor
- Novartis
- Target Recruit Count
- 49
- Registration Number
- NCT00481676
- Locations
- 🇩🇪
Novartis Investigative Site, Munich, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath